28
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.

      1 ,
      Annual review of pharmacology and toxicology
      Annual Reviews

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dramatic advances in understanding of the roles RNA plays in normal health and disease have greatly expanded over the past 10 years and have made it clear that scientists are only beginning to comprehend the biology of RNAs. It is likely that RNA will become an increasingly important target for therapeutic intervention; therefore, it is important to develop strategies for therapeutically modulating RNA function. Antisense oligonucleotides are perhaps the most direct therapeutic strategy to approach RNA. Antisense oligonucleotides are designed to bind to the target RNA by well-characterized Watson-Crick base pairing, and once bound to the target RNA, modulate its function through a variety of postbinding events. This review focuses on the molecular mechanisms by which antisense oligonucleotides can be designed to modulate RNA function in mammalian cells and how synthetic oligonucleotides behave in the body.

          Related collections

          Author and article information

          Journal
          Annu Rev Pharmacol Toxicol
          Annual review of pharmacology and toxicology
          Annual Reviews
          1545-4304
          0362-1642
          2010
          : 50
          Affiliations
          [1 ] Isis Pharmaceuticals, Inc., Carlsbad, California 92008, USA. fbennett@isisph.com
          Article
          10.1146/annurev.pharmtox.010909.105654
          20055705
          da054d6c-9298-42dd-a45f-401cd547d90e
          History

          Comments

          Comment on this article